Tuberculosis (TB) is a leading cause of death worldwide and its impact has intensified due to the emergence of multi drug-resistant (MDR) and extensively drug-resistant (XDR) tB strains. protein phosphorylation plays a vital role in the virulence of Mycobacterium tuberculosis (M.tb) mediated by protein kinases. protein tyrosine phosphatase A (MptpA) undergoes phosphorylation by a unique tyrosine-specific kinase, protein tyrosine kinase A (PtkA), identified in the M.tb genome. ptkA phosphorylates PtpA on the tyrosine residues at positions 128 and 129, thereby increasing PtpA activity and promoting pathogenicity of MptpA. In the present study, we performed an extensive investigation of the conformational behavior of the intrinsically disordered domain (iDD) of ptkA using replica exchange molecular dynamics simulations. Long-term molecular dynamics (MD) simulations were performed to elucidate the role of iDD on the catalytic activity of kinase core domain (KcD) of ptkA. This was followed by identification of the probable inhibitors of PtkA using drug repurposing to block the PtpA-PtkA interaction. The inhibitory role of IDD on KCD has already been established; however, various analyses conducted in the present study showed that iDD ptkA had a greater inhibitory effect on the catalytic activity of KcD ptkA in the presence of the drugs esculin and inosine pranobex. the binding of drugs to PtkA resulted in formation of stable complexes, indicating that these two drugs are potentially useful as inhibitors of M.tb. Mycobacterium tuberculosis (M.tb) is an infectious agent that causes tuberculosis (TB) which is an airborne disease that affects almost one third of the world population. The Global Tuberculosis Report (2018), published by World Health Organization, estimated 1.3 million deaths and around 10 million new cases due to TB 1. The currently available treatments for TB include first-line drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide), second-line injectable drugs (amikacin, kanamycin, and capreomycin), and fluoroquinolones in combination with the second-line drugs. Drug-resistant TB has emerged due to factors that include improper treatment; poor quality, limited supply and cost of drugs; person-to-person transmission of resistant bacteria; and poor compliance. Drug resistance is now a major obstacle to effective global TB management and prevention 2. In 2017, 30% of the 6.7 million new or TB relapse cases were reported to have resistance to rifampicin (the first-line drug of treatment) worldwide. Thus, the need of the hour is to develop novel, effective, and safer treatment strategies for the treatment of multidrug resistant (MDR) and extensively drug resistant (XDR) TB. However, the process of drug development, which includes a series of steps starting from pre-clinical studies to clinical trials, is time, cost, and labor extensive. This has resulted in a lack of new molecules that could be further developed and approved by the FDA for successful incorporation into anti-TB treatment strategies. Drug r...